Immatics N.V. (IMTX)
IMTX Stock Price Chart
Explore Immatics N.V. interactive price chart. Choose custom timeframes to analyze IMTX price movements and trends.
IMTX Company Profile
Discover essential business fundamentals and corporate details for Immatics N.V. (IMTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Dec 2018
Employees
554.00
Website
https://www.immatics.comCEO
Harpreet Singh
Description
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
IMTX Financial Timeline
Browse a chronological timeline of Immatics N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.48, while revenue estimate is $11.73m.
Earnings released on 12 May 2026
EPS came in at -$0.50 falling short of the estimated -$0.42 by -19.05%, while revenue for the quarter reached $8.78m , missing expectations by -10.34%.
Earnings released on 5 Mar 2026
EPS came in at -$0.34 surpassing the estimated -$0.48 by +29.17%, while revenue for the quarter reached $22.32m , beating expectations by +98.16%.
Earnings released on 17 Nov 2025
EPS came in at -$0.49 falling short of the estimated -$0.44 by -11.53%, while revenue for the quarter reached $6.08m , missing expectations by -43.26%.
Earnings released on 13 Aug 2025
EPS came in at -$0.66 falling short of the estimated -$0.38 by -73.68%, while revenue for the quarter reached $5.58m , missing expectations by -55.48%.
Earnings released on 13 May 2025
EPS came in at -$0.35 surpassing the estimated -$0.39 by +10.26%, while revenue for the quarter reached $20.37m , beating expectations by +50.79%.
Earnings released on 27 Mar 2025
EPS came in at $0.48 surpassing the estimated -$0.33 by +245.45%, while revenue for the quarter reached $58.25m , beating expectations by +145.60%.
Earnings released on 18 Nov 2024
EPS came in at -$0.12 surpassing the estimated -$0.27 by +55.56%, while revenue for the quarter reached $55.45m , beating expectations by +243.21%.
Earnings released on 13 Aug 2024
EPS came in at -$0.18 surpassing the estimated -$0.35 by +48.57%, while revenue for the quarter reached $20.17m , beating expectations by +35.34%.
Earnings released on 14 May 2024
EPS came in at -$0.04 surpassing the estimated -$0.74 by +94.59%, while revenue for the quarter reached $32.71m , beating expectations by +48.68%.
Earnings released on 21 Mar 2024
EPS came in at -$0.32 surpassing the estimated -$0.41 by +21.95%, while revenue for the quarter reached $17.51m , beating expectations by +6.96%.
Earnings released on 14 Nov 2023
EPS came in at -$0.35 surpassing the estimated -$0.42 by +16.67%, while revenue for the quarter reached $6.25m , missing expectations by -58.98%.
Earnings released on 17 Aug 2023
EPS came in at -$0.35 falling short of the estimated -$0.34 by -2.94%, while revenue for the quarter reached $24.39m , beating expectations by +9.50%.
Earnings released on 16 May 2023
EPS came in at -$0.28 surpassing the estimated -$0.35 by +20.00%, while revenue for the quarter reached $10.65m , missing expectations by -17.76%.
Earnings released on 21 Mar 2023
EPS came in at -$0.23 falling short of the estimated $0.17 by -235.29%, while revenue for the quarter reached $40.55m , beating expectations by +78.73%.
Earnings released on 17 Nov 2022
EPS came in at -$0.32 falling short of the estimated -$0.31 by -3.23%, while revenue for the quarter reached $14.71m .
Earnings released on 9 Aug 2022
EPS came in at -$0.23 falling short of the estimated $0.13 by -276.92%, while revenue for the quarter reached $18.01m , missing expectations by -28.95%.
Earnings released on 2 Jun 2022
EPS came in at $1.35 falling short of the estimated $1.76 by -23.30%, while revenue for the quarter reached $113.83m , missing expectations by -28.13%.
Earnings released on 23 Mar 2022
EPS came in at -$0.30 falling short of the estimated $1.94 by -115.46%, while revenue for the quarter reached $17.83m , beating expectations by +65.99%.
Earnings released on 16 Nov 2021
EPS came in at -$0.51 falling short of the estimated -$0.31 by -64.52%, while revenue for the quarter reached $7.48m , missing expectations by -37.38%.
Earnings released on 10 Aug 2021
EPS came in at -$0.46 falling short of the estimated -$0.38 by -21.05%, while revenue for the quarter reached $6.16m , missing expectations by -38.50%.
IMTX Stock Performance
Access detailed IMTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
